PDL BioPharma, Inc. (NASDAQ:PDLI) Files An 8-K Submission of Matters to a Vote of Security Holders

Broker Non-Votes

ME Staff 8-k

8 years ago

PDL BioPharma, Inc. (NASDAQ:PDLI) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 9, 2017, the Company held its 2017 Annual Meeting of
Stockholders in Incline Village, Nevada. At the annual meeting,
the Companys stockholders: (i) elected each of David Gryska and
Paul Sandman to the Companys Board of Directors for a term of
three years, (ii) ratified the appointment of
PricewaterhouseCoopers LLP as the Companys independent registered
public accounting firm for the fiscal year ending December 31,
2017, (iii) approved, on an advisory basis, the compensation of
the Companys named executive officers as disclosed in the
Companys proxy statement and (iv) indicated, on an advisory
basis, that every year is the preferred frequency for stockholder
advisory votes on the compensation of the Companys named
executive officers.

Represented in person or by proxy at the annual meeting were
130,238,633 shares of the Companys common stock, or 80.51% of the
total number of shares outstanding as of the record date. The
results of the matters submitted to a stockholder vote at the
annual meeting were as follows.

1. Election of Directors:



Name	For	Withheld	Broker Non-Votes
David Gryska	91,324,115	2,893,462	36,021,056
Paul Sandman	91,398,485	2,819,092	36,021,056


2.	Ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017:



For	Against	Abstain
128,384,271	1,352,115	502,247


3.	Approve, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the Companys proxy statement:


4.	Indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Companys named executive officers:



Every Year	Every 2 Years	Every 3 Years	Abstain	Broker Non-Votes
81,626,699	476,558	11,693,831	420,489	36,021,056

About PDL BioPharma, Inc. (NASDAQ:PDLI)
PDL BioPharma, Inc., formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions and inventors. It evaluates its investments based on the quality of the income generating assets and potential returns on investment. It is focused on intellectual property asset management, acquiring income generating assets and maximizing value for its stockholders, among others. It receives royalties on sales of over ten humanized antibody products, which include Avastin, Herceptin, Xolair, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio all of which are approved for use.